Search results for "OUTCOME"

showing 10 items of 5148 documents

Early Response to treatment in Eating Disorders: A Systematic Review and a Diagnostic Test Accuracy Meta-Analysis

2016

Objective: Early response to eating disorders treatment is thought to predict a later favourable outcome. A systematic review of the literature and meta-analyses examined the robustness of this concept. Method: The criteria used across studies to define early response were summarised following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Diagnostic Test Accuracy methodology was used to estimate the size of the effect. Results: Findings from 24 studies were synthesized and data from 14 studies were included in the meta-analysis. In Anorexia Nervosa, the odds ratio of early response predicting remission was 4.85(95%CI: 2.94–8.01) and the summary Area Unde…

Time FactorsAnorexia NervosaDiagnostic Tests RoutineReproducibility of Resultscognitive behavioural therapyearly responseFeeding and Eating DisordersClinical PsychologyTreatment OutcomePsychiatry and Mental Healtheating disorderSettore M-PSI/08 - Psicologia Clinicabinge eating disorderHumansfamily therapyBulimia NervosaBinge-Eating DisorderRandomized Controlled Trials as Topic
researchProduct

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD

2012

Bronchodilators are central in the symptomatic management of chronic obstructive pulmonary disease (COPD). Long-acting muscarinic antagonists (LAMAs) and long-acting β(2)-agonists (LABAs) are the main classes of long-acting bronchodilators. To date, tiotropium is the only once-daily LAMA available for the treatment of COPD. Glycopyrronium is a novel LAMA, currently in development for COPD. Phase II studies have shown that glycopyrronium 50 μg once daily provides clinically significant 24-hour bronchodilation with a rapid onset of action, which is faster than that of tiotropium, and a favorable safety and tolerability profile. The Phase III GLycopyrronium bromide in COPD airWays (GLOW) progr…

Time FactorsCombination therapymuscarinic antagonistReviewMuscarinic AntagonistsPlaceboNVA237Severity of Illness IndexDrug Administration Schedulechronic obstructive pulmonary diseaseglycopyrroniumPulmonary Disease Chronic ObstructiveAdministration InhalationHumansMedicineGlycopyrronium bromideAdverse effectLungCOPDExercise Tolerancebiologybusiness.industryGeneral MedicineLamamedicine.diseasebiology.organism_classificationonce dailyGlycopyrrolateBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeTolerabilityAnesthesiaIndacaterolbusinessmedicine.drugInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Associations of Maternal Cell-Phone Use During Pregnancy With Pregnancy Duration and Fetal Growth in 4 Birth Cohorts

2019

Results from studies evaluating potential effects of prenatal exposure to radio-frequency electromagnetic fields from cell phones on birth outcomes have been inconsistent. Using data on 55,507 pregnant women and their children from Denmark (1996-2002), the Netherlands (2003-2004), Spain (2003-2008), and South Korea (2006-2011), we explored whether maternal cell-phone use was associated with pregnancy duration and fetal growth. On the basis of self-reported number of cell-phone calls per day, exposure was grouped as none, low (referent), intermediate, or high. We examined pregnancy duration (gestational age at birth, preterm/postterm birth), fetal growth (birth weight ratio, small/large size…

Time FactorsEpidemiologyDenmarkOriginal ContributionsFetal Developmentstress0302 clinical medicinePregnancyRisk FactorsFetal growthBirth outcomes030212 general & internal medicineNetherlandsObstetricsConfoundingHazard ratio1. No povertyPregnancy OutcomeGestational age3. Good healthbehavioral-problems1st trimesterPremature birth030220 oncology & carcinogenesisPremature BirthFemaleAdultmedicine.medical_specialtyradio-frequency electromagnetic fieldsBirth weightCell phonescell phonesGestational AgeExposure03 medical and health sciencesRepublic of KoreamedicineHumansradio-frequency electronRadio-frequency electromagnetic fieldsPregnancybusiness.industryabsorption ratesbirth outcomespreterm birthweightPreterm birthmedicine.diseaseConfidence intervalwhole-bodyradiationSpainexposurebusinessCell PhoneAmerican Journal of Epidemiology
researchProduct

The Artificial Kidney Initiation in Kidney Injury 2 (AKIKI2): study protocol for a randomized controlled trial

2019

Abstract Background The Artificial Kidney Initiation in Kidney Injury (AKIKI) trial showed that a delayed renal replacement therapy (RRT) strategy for severe acute kidney injury (AKI) in critically ill patients was safe and associated with major reduction in RRT initiation compared with an early strategy. The five criteria which mandated RRT initiation in the delayed arm were: severe hyperkalemia, severe acidosis, acute pulmonary edema due to fluid overload resulting in severe hypoxemia, serum urea concentration > 40 mmol/l and oliguria/anuria > 72 h. However, duration of anuria/oliguria and level of blood urea are still criteria open to debate. The objective of the study is to compar…

Time FactorsHyperkalemiamedicine.medical_treatment[SDV]Life Sciences [q-bio]Medicine (miscellaneous)030204 cardiovascular system & hematologyKidneyurologic and male genital diseases[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrologylaw.inventionTime-to-Treatment03 medical and health sciencesStudy Protocol0302 clinical medicineRandomized controlled triallawOliguriamedicineHumansMulticenter Studies as TopicPharmacology (medical)030212 general & internal medicineRenal replacement therapyProspective StudiesTreatment outcomeRandomized Controlled Trials as TopicMechanical ventilationlcsh:R5-920business.industryRenal replacement therapyAcute kidney injuryRecovery of FunctionInterim analysismedicine.diseasefemale genital diseases and pregnancy complications3. Good healthAcute kidney injuryCritical careAnesthesiaAnuria[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFrancemedicine.symptombusinesslcsh:Medicine (General)Kidneys Artificial
researchProduct

A central nervous system-focused treatment approach for people with frozen shoulder: protocol for a randomized clinical trial

2019

Background: Frozen shoulder (FS) is a musculoskeletal condition of poorly understood etiology that results in shoulder pain and large mobility deficits. Despite some physical therapy interventions, such as joint mobilization and exercise, having shown therapeutic benefit, a definitive treatment does not currently exist. The aim of this study will be to compare the effectiveness of a central nervous system (CNS)-directed treatment program versus a standard medical and physical therapy care program on outcomes in participants with FS. Methods/design: The study is a two-group, randomized clinical trial with blinding of participants and assessors. Participants will be recruited via referrals fr…

Time FactorsJoint mobilizationDolor de hombro:Phenomena and Processes::Physical Phenomena::Time::Time Factors [Medical Subject Headings]Shoulder painShoulder adhesive capsulitisPsychological interventionMedicine (miscellaneous)law.invention:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Disability EvaluationStudy ProtocolDiscrimination Psychological0302 clinical medicineRandomized controlled trialFeedback Sensorylaw:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Physical Therapy Modalities [Medical Subject Headings]:Diseases::Musculoskeletal Diseases::Joint Diseases::Bursitis [Medical Subject Headings]Pharmacology (medical)030212 general & internal medicineRange of Motion ArticularPhysiotherapyFisioterapiaRandomized Controlled Trials as Topic:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Controlled Clinical Trials as Topic::Randomized Controlled Trials as Topic [Medical Subject Headings]lcsh:R5-920Shoulder JointFrozen shoulder:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Disability Evaluation [Medical Subject Headings]Treatment OutcomeCohortlcsh:Medicine (General):Anatomy::Musculoskeletal System::Skeleton::Joints::Shoulder Joint [Medical Subject Headings]medicine.medical_specialtyBlindingSensationContext (language use)03 medical and health sciencesBursitismedicineHumansPhysical Therapy Modalities:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings]:Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings]:Anatomy::Nervous System::Central Nervous System [Medical Subject Headings]business.industry:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Range of Motion Articular [Medical Subject Headings]Recovery of FunctionCapsulitismedicine.disease:Phenomena and Processes::Biological Phenomena::Recovery of Function [Medical Subject Headings]Sistema nervioso central:Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Nervous System Physiological Phenomena::Nervous System Physiological Processes::Sensation [Medical Subject Headings]SpainCentral nervous systemOrthopedic surgeryShoulder adhesivePhysical therapy:Phenomena and Processes::Physiological Phenomena::Physiological Processes::Homeostasis::Feedback Physiological::Feedback Sensory [Medical Subject Headings]business030217 neurology & neurosurgery
researchProduct

An overview of the clinical efficacy of mirtazapine

2002

Mirtazapine is at least as effective as the tricyclic antidepressants and trazodone in a wide range of patient subgroups including in- and out-patients with moderate to severe depression. It also appears to be at least as effective as the serotonin and noradrenaline reuptake inhibitor venlafaxine in the treatment of severely depressed melancholic patients. When compared with the selective serotonin reuptake inhibitors (SSRIs), mirtazapine shows a significantly earlier onset of action. Further analysis of a study comparing mirtazapine with the SSRI paroxetine indicated that early improvement was a highly sensitive predictor of later stable response for both drugs. The positive predictive val…

Time FactorsMirtazapineVenlafaxine HydrochlorideMirtazapineVenlafaxineMianserinAntidepressive Agents TricyclicPharmacologymedicineHumansPharmacology (medical)chemistry.chemical_classificationClinical Trials as TopicDepressive DisorderAdrenergic Uptake Inhibitorsbusiness.industryVenlafaxine HydrochlorideTrazodoneCyclohexanolsParoxetineAntidepressive AgentsParoxetinePsychiatry and Mental healthTreatment OutcomeNeurologychemistryNeurology (clinical)SerotoninOnset of actionbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugTricyclicHuman Psychopharmacology: Clinical and Experimental
researchProduct

Extranodal extension in N1-adenocarcinoma of the pancreas and papilla of Vater: A systematic review and meta-analysis of its prognostic significance

2016

The aim of the study was to investigate the prognostic role of extranodal extension (ENE) of lymph node metastasis in adenocarcinoma of the pancreas (PDAC) and papilla [cancer of the papilla of Vater (CPV)]. A PubMed and SCOPUS search from database inception until 5 January 2015 without language restrictions was conducted. Eligible were prospective studies reporting data on prognostic parameters in individuals with PDAC and/or CPV, comparing participants with the presence of ENE (ENE +) with those with intranodal extension (ENE). Data were summarized using risk ratios for number of deaths/recurrences and hazard ratios for time-dependent risk related to ENE+, adjusted for potential confounde…

Time FactorsPapillaPapillary carcinomaGastroenterologyextranodal extension pancreatic adenocarcinoma papilla papillary carcinoma prognosislymph node metastasis adenocarcinoma of the pancreas (PDAC) papilla [cancer of the papilla of Vater (CPV)] extranodal extension (ENE)0302 clinical medicineRisk FactorsOdds RatioProspective cohort studylymph node metastasisHazard ratioAmpulla of VaterGastroenterologyPrognosisextranodal extension (ENE)medicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisLymphatic Metastasisadenocarcinoma of the pancreas (PDAC)Disease ProgressionAdenocarcinoma030211 gastroenterology & hepatologymedicine.medical_specialtyAmpulla of VaterCommon Bile Duct NeoplasmsAdenocarcinomapapilla [cancer of the papilla of Vater (CPV)]Disease-Free Survival03 medical and health sciencesExtranodal extension; Pancreatic adenocarcinoma; Papilla; Papillary carcinoma; Prognosis; Gastroenterology; HepatologyPredictive Value of TestsInternal medicineExtranodal extensionmedicineHumansHepatologybusiness.industryOdds ratiomedicine.diseaseConfidence intervalSurgeryMajor duodenal papillaPancreatic NeoplasmsRelative riskLymph NodesNeoplasm Recurrence LocalbusinessPancreatic adenocarcinoma
researchProduct

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life

2016

Marco Contoli,1 Paolo Solidoro,2 Fabiano Di Marco,3,4 Nicola Scichilone,5 Angelo Corsico,6 Fulvio Braido,7 Pierachille Santus4,8 1Research Centre on Asthma and COPD, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; 2Cardiovascular and Thoracic Department, Città della Salute, Turin, Italy; 3Department of Health Sciences, University of Milan, Milan, Italy; 4Respiratory Unit, San Paolo Hospital, Milan, Italy; 5Department of Internal Medicine, Section of Pulmonology (DIBIMIS), University of Palermo, Palermo, Italy; 6Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 7Allergy and Respiratory Diseases Clinic, DIMI, University of G…

Time FactorsReviewdaily symptomsAclidinium; COPD; Daily symptoms; LAMA; Quality of life; Pulmonary and Respiratory Medicine; Health Policy; Public Health Environmental and Occupational HealthSeverity of Illness IndexPulmonary Disease Chronic Obstructive0302 clinical medicineBronchodilatorMedicine030212 general & internal medicineLungCOPDHealth PolicyTropaneLAMAGeneral MedicineBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeTolerabilityChronic inflammatory responsePublic HealthHumanPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtyTime Factormedicine.drug_classBronchoconstrictionSocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease03 medical and health sciencesAclidinium bromideaclidiniumAclidinium; COPD; Daily symptoms; LAMA; Quality of life; Bronchoconstriction; Bronchodilator Agents; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Recovery of Function; Severity of Illness Index; Time Factors; Treatment Outcome; Tropanes; Quality of LifeInternal medicineSeverity of illnessAnticholinergicCOPDHumansAdverse effectBronchodilator Agentlcsh:RC705-779business.industryEnvironmental and Occupational HealthDaily symptomPublic Health Environmental and Occupational Healthlcsh:Diseases of the respiratory systemRecovery of Functionmedicine.diseasequality of life030228 respiratory systemPhysical therapybusinessTropanesInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Management of HCV-Related Liver Disease in Hemophilia and Thalassemia

2018

AbstractChronic infection with the hepatitis C virus (HCV) has long been the dominant complication of substitution therapy in patients with inherited blood disorders and the cause of anticipated death due to end-stage liver disease. In hemophilia, transmission of HCV with clotting factors concentrates started to be curbed in the mid-1980s following the adoption of procedures of virus inactivation of concentrates based on heat, whereas in the 1990s treatment of HCV infection with interferon monotherapy was attempted, however, with little success. The advent of combination therapy of interferon with ribavirin led to a substantial improvement of treatment outcome (40% rate of cure), that howev…

Time FactorsTime FactorThalassemiaHepatitis C virusPopulationAdministration Oral030204 cardiovascular system & hematologyHemophilia Amedicine.disease_causeAntiviral Agents03 medical and health scienceschemistry.chemical_compoundLiver disease0302 clinical medicinesickle cell anemiaRisk FactorshemophiliamedicineHumansBlood TransfusioneducationImmunodeficiencyAntiviral AgentClotting factoreducation.field_of_studydirect antiviral agentHepatologybusiness.industryRisk FactorRibavirinHepatitis CHepatitis C Chronicmedicine.diseaseTreatment OutcomechemistryImmunologyThalassemiaDrug Therapy Combination030211 gastroenterology & hepatologyhepatitis CbusinessHumanSeminars in Liver Disease
researchProduct

Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women

2014

AIM: To investigate the safety/efficacy of Boceprevirbased triple therapy in hepatitis C virus (HCV)-G1 menopausal women who were historic relapsers, partial-responders and null-responders. METHODS: In this single-assignment, unblinded study, we treated fifty-six menopausal women with HCV-G1, 46% F3-F4, and previous PEG-α/RBV failure (7% null, 41% non-responder, and 52% relapser) with 4 wk lead-in with PEG-IFNα2b/RBV followed by PEGIFNα2b/RBV+Boceprevir for 32 wk, with an additional 12 wk of PEG-IFN-α-2b/RBV if patients were HCV-RNA-positive by week 8. In previous null-responders, 44 wk of triple therapy was used. The primary objective of retreatment was to verify whether a sustained virolo…

Time FactorsViral HepatitisClinical Trials StudyHepacivirusViral hepatitiPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundPegylated interferonOdds RatioMultivariate AnalysiPegylated InterferonGastroenterologyGeneral MedicineHepatitis CHepatitis c virus treatmentMiddle AgedRecombinant ProteinViral LoadGenotype 1Recombinant ProteinsMenopauseTreatment OutcomeItalyRNA ViralDrug Therapy CombinationFemaleMenopauseViral hepatitisViral loadPegylated interferonHumanmedicine.drugmedicine.medical_specialtyGenotypeLogistic ModelProlineTime FactorInterferon alpha-2Hepatitis C virus treatmentAntiviral AgentsPharmacotherapyInternal medicineBoceprevirRibavirinmental disordersmedicineHumansAntiviral AgentHepacivirubusiness.industryInterferon-alphaBiomarkerGenotype 1; Hepatitis c virus treatment; Menopause; Pegylated interferon; Viral hepatitis; Antiviral Agents; Biomarkers; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Logistic Models; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proline; RNA Viral; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Menopause; GastroenterologyHepatitis C Chronicmedicine.diseaseVirologyLogistic ModelschemistryHepatitis C Virus PositiveMultivariate AnalysisGenotype 1; Hepatitis C virus treatment; Menopause; Pegylated Interferon; Viral HepatitisbusinessBiomarkers
researchProduct